Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) Operating Expenses: 2021-2025

Historic Operating Expenses for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$16.6 million.

  • ProQR Therapeutics N.V's Operating Expenses fell 19.04% to -$16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year increase of 8.21%. This contributed to the annual value of $53.4 million for FY2024, which is 19.39% up from last year.
  • ProQR Therapeutics N.V's Operating Expenses amounted to -$16.6 million in Q3 2025, which was up 9.61% from -$18.4 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's Operating Expenses registered a high of $127.9 million during Q4 2022, and its lowest value of -$20.9 million during Q3 2022.
  • Moreover, its 3-year median value for Operating Expenses was -$10.9 million (2023), whereas its average is $4.2 million.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Operating Expenses skyrocketed by 729.12% in 2022, and later plummeted by 69.50% in 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's Operating Expenses (Quarterly) stood at -$20.3 million in 2021, then skyrocketed by 729.12% to $127.9 million in 2022, then crashed by 40.88% to $75.6 million in 2023, then climbed by 20.83% to $91.4 million in 2024, then dropped by 19.04% to -$16.6 million in 2025.
  • Its Operating Expenses was -$16.6 million in Q3 2025, compared to -$18.4 million in Q2 2025 and -$16.4 million in Q1 2025.